CLL Panel Fluorescence In Situ Hybridization

The CLL Panel Fluorescence In Situ Hybridisation (FISH) test is a specialised cytogenetic test used to detect specific chromosomal abnormalities in patients with Chronic Lymphocytic Leukemia (CLL), the most common type of leukemia in adults. CLL is a slow-progressing blood cancer in which the bone marrow produces too many abnormal lymphocytes that gradually crowd out healthy blood cells. FISH is a highly sensitive laboratory technique that uses fluorescent probes - small pieces of DNA labelled with fluorescent dyes - that bind to specific regions of chromosomes and highlight any deletions, duplications, or rearrangements present in the cancer cells. The CLL FISH Panel specifically looks for key chromosomal changes such as deletion 13q, deletion 11q, deletion 17p, trisomy 12, and TP53 mutations, all of which carry significant prognostic and therapeutic implications. Together, these findings help oncologists and haematologists understand how the disease is likely to behave and which treatment approach is best suited for the patient.

Who Should Get This Test Done?

The CLL Panel FISH test is recommended for individuals who:

●      Have been newly diagnosed with CLL and require chromosomal profiling for risk stratification

●      Have an unexplained and persistent increase in lymphocyte count detected on routine blood tests

●      Show symptoms such as swollen lymph nodes, unexplained weight loss, night sweats, or persistent fatigue

●      Are about to begin treatment for CLL and need molecular guidance for therapy selection

●      Have CLL and are being considered for targeted therapies such as BTK inhibitors or BCL-2 inhibitors

Why Consider This Test?
Not all cases of CLL follow the same clinical course - some patients live with the disease for many years without needing treatment, while others experience rapid progression that requires prompt intervention. The chromosomal abnormalities detected by the CLL FISH Panel are among the strongest predictors of how the disease will behave. For instance, deletion 17p and TP53 mutations are associated with high-risk disease and poor response to standard chemotherapy, making it essential to identify them early so that alternative treatment strategies can be considered. On the other hand, deletion 13q as the sole abnormality is generally associated with a more favourable prognosis. This level of prognostic detail is simply not available through routine blood tests or conventional microscopy. Getting this test done gives both the patient and the treating doctor a much clearer picture of what lies ahead and how best to approach the disease from the very beginning.
More Information

The CLL Panel FISH test is performed on a peripheral blood sample or bone marrow aspirate, with peripheral blood being the more commonly used sample type in CLL cases due to the typically high number of circulating leukemic cells. The fluorescent probes used in the test are designed to target chromosomal regions that are most clinically relevant in CLL, and the analysis is carried out under a fluorescence microscope by a trained cytogeneticist. Results are typically available within a few days to a week (Terms and Conditions apply) and are reported as a percentage of cells carrying each abnormality, along with the clinical significance of the findings. Since chromosomal abnormalities in CLL can change over time - a phenomenon known as clonal evolution -  repeat FISH testing may be recommended at the time of disease progression or before initiating a new line of treatment.

Other Names

The CLL Panel FISH test may also be referred to as:

●      CLL Cytogenetics Panel

●      Chronic Lymphocytic Leukemia FISH Panel

●      CLL Chromosomal Abnormality Panel

●      CLL Prognostic FISH Panel

●      Leukemia FISH Panel

●      CLL Deletion Panel

●      CLL Molecular Cytogenetics Test